Big drugmakers will halt clinical trials at some hospitals in China


Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military.

The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.

All five companies indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, which is the military wing of the Chinese Communist Party. In letters sent to the drugmakers, the House committee noted rising concern over the possibility of security risks.

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe



Source link

एक उत्तर छोड़ें

आपका ईमेल पता प्रकाशित नहीं किया जाएगा। आवश्यक फ़ील्ड को * से चिह्नित किया गया है